🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

14,283 results for “B” Clear

  1. Cognitive Behavioral Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Abuse

    phase 3 other completed

    1 trial

  2. Cognitive Behavioral Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    Stress Disorders, Post-Traumatic

    phase 3 other completed

    1 trial

  3. Cohort 1: Lubiprostone Capsule, Fasted

    Takeda

    Healthy Volunteers

    phase 3 small molecule completed

    1 trial

  4. Colchicine 0.5 mg

    The George Institute

    Intracerebral Hemorrhage

    phase 3 small molecule active

    1 trial

  5. Cold Stored Platelets

    United Therapeutics Europe Ltd

    Acute Blood Loss

    phase 3 mab completed

    1 trial

  6. Combination Treatment of PDS0101 and Pembrolizumab

    PDS Biotechnology Corp

    Recurrent Head and Neck Cancer

    phase 3 other active

    1 trial

  7. Combined use of TPO-RAs with low-dose anti-CD20 antibody

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Immune Thrombocytopenia (ITP)

    phase 3 small molecule active

    1 trial

  8. Combipress 150 mg/5 mg επικαλυμμένα με λεπτό υμένιο δισκία, Combipress 150 mg/10 mg επικαλυμμένα με λεπτό υμένιο δισκία, Combipress 300 mg/10 mg επικαλυμμένα με λεπτό υμένιο δισκία, Combipress 300 mg/5 mg επικαλυμμένα με λεπτό υμένιο δισκία

    Lacuna Pharma Pty Ltd

    Arterial Hypertension

    phase 3 small molecule active

    1 trial

  9. Commercially available 0,9 % sterile saline solution with marketing authorization will be utilized as the placebo., KEYTRUDA 25 mg/mL concentrate for solution for infusion, INBRX-106, INBRX-106

    Inhibrx Biosciences

    Head and Neck Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  10. Conceptrol

    Evofem Biosciences

    Contraception

    phase 3 small molecule completed

    1 trial

  11. Concizumab

    Novo Nordisk A/S

    Haemophilia A Without Inhibitors

    phase 3 small molecule active

    1 trial

  12. Concizumab

    Novo Nordisk A/S

    Haemophilia A With Inhibitors

    phase 3 small molecule active

    1 trial

  13. Concizumab C 100 mg/mL PDS290, Concizumab C 40 mg/mL PDS290

    NovoThirteen

    haemophilia A (HA) with inhibitors and haemophilia B (HB) with inhibitors

    phase 3 small molecule active

    1 trial

  14. Concizumab C 100 mg/mL PDS290, Concizumab C 40 mg/mL PDS290, Concizumab C 10 mg/mL PDS290

    NovoThirteen

    Haemophilia A or B with or without inhibitors

    phase 3 small molecule active

    1 trial

  15. Concizumab C 40 mg/mL PDS290, Concizumab C 100 mg/mL PDS290

    NovoThirteen

    haemophilia A (HA) without inhibitors and haemophilia B (HB) without inhibitors

    phase 3 small molecule active

    1 trial

  16. Conivaptan hydrochloride

    CUMBERLAND PHARMACEUTICALS INC

    Hyponatremia

    phase 3 small molecule terminated

    1 trial

  17. Conjunctival Provocation Test Grass-Mix LETI 30 HEP/ml, Conjunctival Provocation Test Olea europaea LETI 30 HEP/ml, Depigoid DUO Grass-Mix/Olea (1000 DPP/ml + 1000 DPP/ml), PLACEBO (Depigoid): the placebo is the solvent used in the investigational medicinal products’ (IMP) formulation. The resulting product is a suspension.

    Lacuna Pharma Pty Ltd

    Allergic rhinoconjunctivitis with or without asthma due to clinically relevant sensitisation to grass and olive pollen.

    phase 3 small molecule active

    1 trial

  18. Continuous Gastrocnemius plane block with ropivacaine

    The First People's Hospital of Lianyungang

    Foot Ankle Injuries

    phase 3 small molecule active

    1 trial

  19. Control

    Hospital Authority, Hong Kong

    Hallucinations, Verbal Auditory

    phase 3 small molecule active

    1 trial

  20. Conventional sound generator (SG)

    Camp4 Therapeutics Corp

    Subjective Tinnitus

    phase 3 other completed

    1 trial

  21. Copanlisib (Aliqopa, BAY80-6946)

    Bayer HealthCare AG

    Lymphoma,Non-Hodgkin

    phase 3 small molecule completed

    1 trial

  22. Copiktra 25 mg hard capsules, Copiktra 15 mg hard capsules, DUVELISIB , BENDAMUSTINE , GEMCITABINE

    Secura Bio Limited

    relapsed/refractory nodal T cell lymphoma with T follicular helper (TFH) phenotype, relapsed/refractory nodal T cell lymphoma with T follicular helper (TFH) phenotype

    phase 3 small molecule active

    1 trial

  23. Coronary Artery Bypass Graft with the use of CPB

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    the Efficacy and Safety of Off-pump CABG

    phase 3 other completed

    1 trial

  24. Coronary artery bypass grafting

    Rhythm Pharmaceuticals Netherlands B.V.

    Ischemic Heart Failure

    phase 3 other completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources